Executive Summary / Key Takeaways

• Transformative Growth Driven by OneRF Ablation: NeuroOne Medical Technologies Corporation (NMTC) is undergoing a significant transformation, fueled by the commercial success of its FDA-cleared OneRF Ablation System, which is the first and only system to combine diagnostic and therapeutic capabilities in a single brain implant. This innovation has driven product revenue growth of 100% year-over-year for the first nine months of fiscal 2025 and expanded gross margins to 56.8%.
• Strategic Partnership with Zimmer Biomet: The expanded exclusive distribution agreement with Zimmer Biomet (ZBH), including a $3.0 million upfront license payment and improved transfer prices, is a cornerstone of NMTC's commercial strategy, providing extensive market reach and accelerating adoption in the epilepsy treatment landscape.
• Diversified Pipeline and Untapped Markets: NMTC is strategically leveraging its thin-film electrode platform into new, high-value markets, including trigeminal nerve ablation for facial pain (FDA-cleared August 2025, potential revenue late 2025), basivertebral nerve ablation for lower back pain, and spinal cord stimulation (SCS) with a $3+ billion annual market opportunity, aiming for first-in-man implants in early 2026.
• Strengthened Financial Position and Clear Guidance: With $8.04 million in cash and cash equivalents as of June 30, 2025, and no outstanding debt following an $8.24 million net proceeds financing in April 2025, NMTC is funded through at least fiscal year 2026. The company reiterates FY25 product revenue guidance of $8.0 million to $10.0 million (excluding license revenue) and increased gross margin expectations to 50%-53%.
• Competitive Moat Through Innovation: NMTC's thin-film technology offers distinct advantages over traditional devices, including minimally invasive procedures, multi-functionality, and enhanced precision, positioning it as an agile innovator against larger, more diversified medical device companies.

A New Era for Neurological Intervention: NeuroOne's Strategic Resurgence

NeuroOne Medical Technologies Corporation (NMTC) is emerging as a compelling player in the medical technology landscape, dedicated to revolutionizing the diagnosis and treatment of neurological disorders. The company's core business revolves around its proprietary thin-film electrode technology, which underpins solutions for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, monitoring, ablation, drug delivery, and brain stimulation. This innovative platform addresses critical needs in conditions such as epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain.

The broader medical device industry for neurological interventions is characterized by a growing demand for less invasive procedures, high-resolution diagnostics, and integrated therapeutic solutions. NMTC's overarching strategy is to capitalize on these trends by developing minimally invasive, high-definition technologies and leveraging strategic partnerships to accelerate market adoption. Its foundational strength lies in its differentiated thin-film electrode technology, which offers distinct advantages over conventional devices.

In this competitive arena, NMTC positions itself as a niche innovator, challenging the established dominance of larger, more diversified players like Medtronic (MDT), Abbott Laboratories (ABT), Boston Scientific (BSX), and Integra LifeSciences (IART). While these industry giants boast extensive global distribution networks, broader product portfolios, and significant R&D budgets, NMTC differentiates itself through specialized technological advancements. The company's agility and focused innovation allow it to develop solutions that may offer superior precision and integrated functionality, potentially carving out significant market share in targeted segments.

The Technological Edge: Precision, Versatility, and the OneRF Platform

At the heart of NeuroOne's investment thesis is its proprietary thin-film electrode technology, a significant differentiator in the neuro-medical device space. This technology forms the basis for its FDA-cleared products and its robust development pipeline.

The flagship OneRF Ablation System exemplifies this technological advantage. It stands as the first and only FDA-cleared RF ablation system for brain procedures that utilizes a single implant for both diagnostic and therapeutic applications. This multi-functional capability offers tangible benefits over traditional, multi-stage procedures. Clinically, it has been shown to reduce the number of hospitalizations and overall procedural time, enhancing patient comfort and safety. For instance, patients can undergo diagnostic mapping and subsequent ablation within a single hospitalization, a significant improvement over conventional methods requiring separate hospital stays months apart. This streamlined approach has already yielded impressive clinical results, with one patient achieving a one-year seizure-free milestone and the majority of treated patients experiencing seizure freedom or significant reductions.

NeuroOne is strategically leveraging this proven OneRF platform for new applications in pain management. The company recently received FDA 510(k) clearance in August 2025 for its OneRF Trigeminal Nerve Ablation System to treat facial pain (trigeminal neuralgia). This marks NMTC's first foray into pain management, targeting a condition affecting approximately 150,000 people in the U.S. annually. A key advantage here is that the same neurosurgeons who perform brain ablations for epilepsy also treat facial pain, creating a natural and efficient market expansion opportunity. The system's multi-contact RF probe allows for precise localization and tailored ablation under temperature-controlled conditions, enhancing safety and accuracy.

Beyond trigeminal neuralgia, the company is actively pursuing basivertebral nerve ablation for lower back pain, involving the percutaneous placement of its OneRF ablation electrode. This initiative is supported by commitments from key physician thought leaders, underscoring its clinical relevance.

In spinal cord stimulation (SCS), NMTC's thin-film percutaneous paddle electrode technology offers a notable competitive edge. It is up to 20 times thinner than traditional electrodes, yet provides broad therapeutic coverage without requiring more invasive surgical implant techniques. A chronic animal study is currently underway, with the potential for first-in-man implants in early 2026. This represents a substantial market opportunity, with the lower back pain segment alone generating over $3 billion in annual revenue.

Furthermore, NMTC is developing an sEEG-based drug delivery system, which has already received its first order from a leading biotech company for testing. This system is designed to both deliver therapeutic agents, such as gene or stem cell therapies, and record brain activity before and after administration. The company aims to deliver a device that is smaller than competitors' offerings, features a larger internal diameter, and crucially, does not require costly and time-consuming real-time MRI for placement.

The "so what" for investors is clear: NeuroOne's technological differentiation is not merely incremental; it is foundational to its competitive moat. These innovations translate into tangible benefits for patients and clinicians, driving adoption and potentially commanding premium pricing in niche markets. The multi-platform approach, leveraging a core thin-film technology across diverse neurological applications, creates a scalable business model. This strategy aims to enhance financial performance through higher average selling prices (ASPs), lower procedural costs, and improved gross margins, while solidifying NMTC's market positioning as a leader in advanced, minimally invasive neuro-technologies. The company's intellectual property portfolio, including a recent notice of allowance for a novel manufacturing method patent and its first international patent for the SCS electrode, further protects these innovations.

Strategic Partnerships and Commercial Momentum

NeuroOne's commercial strategy is deeply intertwined with its strategic partnerships, most notably the exclusive distribution agreement with Zimmer Biomet. This collaboration, which began in 2020 and was significantly expanded in October 2024, is a critical accelerator for NMTC's market penetration. The expanded agreement granted Zimmer exclusive distribution rights for the OneRF Ablation System in the U.S. and certain international geographies.

This partnership has had a profound financial impact. NeuroOne received a $3.0 million upfront license payment and stands to earn an additional $1.0 million milestone payment upon achieving specified net sales thresholds. Crucially, the agreement also includes improved transfer prices, which management explicitly states are expected to significantly boost NeuroOne's revenue potential and profitability. The initial stocking orders to Zimmer Biomet were completed in the first fiscal quarter of 2025, laying the groundwork for broader commercialization.

Zimmer Biomet's "extensive distribution network and scale" are paramount to NMTC's success, providing a "faster time line to mass adoption." With Zimmer's robotic system already prevalent in the majority of epilepsy procedures across approximately 200 Level 4 epilepsy centers in the U.S., NeuroOne gains immediate access to a well-established clinical ecosystem. This strategic alignment helps NMTC compete effectively against the broader distribution capabilities of larger rivals like Medtronic and Abbott.

The commercial momentum is evident in the strong physician interest, with 24 epilepsy centers having requested proposals for the OneRF technology. Clinical validation further underpins this momentum, as patients treated with the OneRF ablation system are demonstrating significant improvements, including many achieving seizure-free status. The system's ability to reduce hospitalizations by enabling both diagnostic and therapeutic applications with a single implant is a compelling value proposition for healthcare providers. Moreover, the new ICD-10 PCS code for the OneRF ablation procedure, effective October 1, 2024, is vital for supporting accurate data collection and reimbursement claims by hospitals, further facilitating broader adoption and strengthening NMTC's competitive standing.

Financial Performance: A Turn Towards Growth and Efficiency

NeuroOne's recent financial performance reflects a company in a period of significant growth and operational efficiency improvements, driven by its strategic initiatives and technological advancements.

For the three months ended June 30, 2025 (Q3 FY25), product revenue surged by 105% year-over-year to $1.70 million, while for the nine months ended June 30, 2025 (YTD FY25), product revenue doubled to $6.36 million compared to the same period in 2024. This robust top-line growth is directly attributed to the commercialization of the higher-margin OneRF Products under the amended Zimmer agreement. Product gross profit for Q3 FY25 reached $0.91 million, translating to an impressive 53.9% gross margin, a substantial increase from 34.1% in Q3 FY24. Similarly, YTD FY25 product gross profit was $3.61 million, with a gross margin of 56.8%, up from 29.5% in YTD FY24. This significant margin expansion underscores the favorable terms of the Zimmer partnership and the inherent profitability of NMTC's core technology.

Beyond product sales, NMTC recognized $3.00 million in license revenue during YTD FY25, stemming from the upfront payment received from Zimmer Biomet for the expanded distribution rights. This non-recurring revenue provided a substantial boost to the company's financial position. Operating expenses have also shown signs of disciplined management. Selling, general and administrative (SG&A) expenses decreased in both the three-month and nine-month periods, primarily due to lower legal and investor relations costs. Research and development (R&D) expenses remained relatively stable, reflecting ongoing investment in the pipeline without a significant increase in burn rate. Consequently, the net loss improved dramatically, shrinking to $1.50 million in Q3 FY25 from $2.77 million in Q3 FY24, and to $1.99 million in YTD FY25 from $8.97 million in YTD FY24.

In terms of liquidity, NeuroOne is in a significantly stronger position. As of June 30, 2025, the company held $8.04 million in cash and cash equivalents and reported working capital of $8.7 million. This robust cash position was bolstered by an oversubscribed public offering in April 2025, which generated approximately $8.24 million in net proceeds. Importantly, NMTC is now debt-free, having terminated a $3.00 million standby secured credit facility in November 2024 after receiving the Zimmer license payment.

Management confidently states that current cash, combined with anticipated product revenues from Zimmer's minimum purchase requirements and improved gross margins, will fund operations through at least fiscal year 2026, with the potential to reach cash flow breakeven if key milestones are achieved.

When comparing NMTC's financial profile to larger competitors, its current gross profit margin of 56.63% (TTM) is competitive with, and in some cases surpasses, those of established players like Medtronic (65%), Abbott (51%), Boston Scientific (61%), and Integra LifeSciences (55%). However, NMTC's negative operating and net profit margins reflect its earlier stage of commercialization and smaller scale, contrasting with the positive, albeit varying, profitability of its larger rivals.

Its higher Price-to-Sales (P/S) ratio of 5.57 (TTM) and Price-to-Book (P/B) ratio of 4.40 (TTM) compared to some competitors suggest that investors are valuing its significant growth potential and innovative technology. While NMTC's financial metrics are still evolving, the rapid improvement in revenue and gross margins, coupled with a strengthened balance sheet, signals a positive trajectory for a company transitioning from R&D to commercial scale.

Outlook and Risks: Charting the Path Ahead

NeuroOne's outlook is characterized by ambitious growth targets and a clear strategic roadmap, though it is not without inherent risks. The company has reiterated its fiscal year 2025 guidance, projecting product revenue in the range of $8.0 million to $10.0 million. This represents a substantial increase of 132% to 190% over fiscal year 2024, notably excluding the $3.0 million upfront license payment from Zimmer. Furthermore, NMTC has increased its product gross margin expectations to between 50% and 53% for FY25, up from previous guidance of 47%-51% and significantly higher than the 31% reported in FY24. This upward revision underscores management's confidence in the profitability of its OneRF products and the favorable terms of the Zimmer partnership. Management anticipates product revenue to ramp through the end of the fiscal year as the product launch expands.

Beyond the core epilepsy market, the recent FDA clearance for the OneRF Trigeminal Nerve Ablation System in August 2025 presents a significant, unquantified upside. Management believes there is potential to generate revenues from this new application as soon as late calendar year 2025, a prospect not yet factored into the current FY25 revenue guidance. Longer-term growth drivers include the potential for first-in-man implants for spinal cord stimulation in early 2026, targeting a multi-billion dollar market, and the continued development of its sEEG-based drug delivery system. International expansion, initiated through ISO 13485 certification, also represents an untapped market with significant future revenue potential.

Despite this optimistic outlook, several risks warrant investor attention. Historically, NeuroOne has incurred losses and negative cash flows since inception, accumulating a deficit of $77.0 million as of June 30, 2025. This history led its independent auditors to include an explanatory paragraph noting substantial doubt about the company's ability to continue as a going concern. While recent financing has bolstered liquidity, the company's future operating activities will require sustained revenue growth to achieve profitability and positive cash flow, which is not assured.

Global economic uncertainties, including international conflicts and inflation, could impact capital access and cost. A significant risk factor is the company's material dependence on its strategic partner, Zimmer Biomet. Zimmer's failure to timely develop or commercialize the distributed products could materially adversely affect NeuroOne's business and operating results. Furthermore, while current funding is projected through fiscal year 2026, the company may need to raise additional capital if anticipated revenues do not materialize or if development activities require more resources, and there is no guarantee such funding would be available on favorable terms. Competitive pressures from larger, well-resourced medical device companies also remain a constant challenge, requiring NMTC to continuously innovate and execute its niche strategy effectively.

Conclusion

NeuroOne Medical Technologies Corporation stands at a pivotal juncture, transforming from an R&D-focused entity into a commercially dynamic medical device company. The core investment thesis hinges on its innovative thin-film electrode technology, particularly the OneRF Ablation System, which has established a unique competitive advantage as the first and only FDA-cleared device for combined diagnostic and therapeutic brain procedures. This technological leadership, coupled with a robust strategic partnership with Zimmer Biomet, is driving significant revenue growth and margin expansion, as evidenced by the strong financial performance in fiscal year 2025.

The company's strategic foresight in expanding its platform into high-growth pain management markets, such as trigeminal nerve ablation and spinal cord stimulation, further solidifies its long-term potential. With a strengthened balance sheet, a debt-free status, and clear guidance for accelerated revenue and margin growth, NeuroOne is well-positioned to execute its ambitious plans. While historical losses and dependence on its commercial partner present inherent risks, the company's differentiated technology, clinical successes, and diversified pipeline offer a compelling narrative for investors seeking exposure to a rapidly innovating segment of the neurological medical device market. The ability to convert its technological prowess into sustained commercial success and achieve cash flow breakeven will be critical indicators of its continued ascent.